Carregando…
RGNX
REGENXBIO Inc.
NASDAQ· Healthcare· Biotechnology
$9.66+3.10%
Indicadores
- Market cap
- $637.69M
- P/L
- —
- P/L projetado
- —
- P/VP
- 7.3x
- Dividend yield
- —
- EPS
- -$3.78
- ROE
- -137.63%
- Margem líquida
- -112.58%
- Crescimento de receita
- +405.70%
- Beta
- 0.94
- Máxima 52 semanas
- $16.19
- Mínima 52 semanas
- $5.46
Histórico
Como a empresa evoluiu, ano a ano. Receita e dívida vêm dos demonstrativos anuais; os dividendos, dos próprios pagamentos, que alcançam mais anos.
As barras são um saldo na data de fechamento; as linhas são o que aconteceu ao longo do ano. Receita acima do patrimônio é o normal, não anomalia — significa que a empresa gira o capital mais de uma vez por ano.
Investidores posicionados
Grandes gestores que reportaram esta ação no 13F mais recente.
Sobre a empresa
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
- 371
- Rockville, United States
Descrição da empresa fornecida pelo Yahoo Finance. A descrição é publicada pela fonte apenas em inglês.